Lihua Zeng, PhD, DrMed, BS

1. Zeng L, Ye J, Zhu L#, Li M. Mechanism of Zuogui Pill in treating premature ovarian insufficiency based on network pharmacology. Journal of Liaoning University of TCM. 2020 Oct 1;22(10):58-65+221. doi: 13194/j.issn.1673-842x.2020.10.016.
2. Zeng L, Zhou Y, Lai Y, Xie B, Gao J, Luo S#. Effects of Jianwei Shoutai Pills on the adhesion function of trophoblast in pregnancy loss based on m⁶A methylation. China Journal of Traditional Chinese Medicine and Pharmacy. 2022 May 1;37(05):2501-2506. doi: CNKI:SUN:BXYY.0.2022-05-017.
3. Zeng L, Zhang Y, Liang Y, Zhang Z, Li J, Zhu L#, et al. Serum metabolomics studies on Zuogui Pills in the treatment of premature ovarian insufficiency rats based on UPLC-Q-TOF-MS. Traditional Chinese Drug Research & Clinical Pharmacology. 2022 Jun 1;33(06):762-769. doi: 19378/j.issn.1003-9783.2022.06.006.
4. Li JW, Chen YZ, Zhang Y, Zeng LH, Li KW, Xie BZ, et al. Gut microbiota and risk of polycystic ovary syndrome: Insights from Mendelian randomization. Heliyon. 2023 Nov 21;9(12):e22155. doi: 10.1016/j.heliyon.2023.e22155. PMID: 38125500; PMCID: PMC10730437. (assisted in revising manuscript)
5. Lai Y, Zhang Y, Zhang H, Chen Z, Zeng L, Deng G, et al. Modified Shoutai Pill inhibited ferroptosis to alleviate recurrent pregnancy loss. J Ethnopharmacol. 2024 Jan 30;319(Pt 2):117028. doi: 10.1016/j.jep.2023.117028. Epub 2023 Aug 18. PMID: 37597678. (ran finger-print chromatogram)
6. Li Z, Liang Y, Wang Y, Lin Y, Zeng L, Zhang Y, et al. Zuogui Pills alleviate cyclophosphamide-induced ovarian aging by reducing oxidative stress and restoring the stemness of oogonial stem cells through the Nrf2/HO-1 signaling pathway. J Ethnopharmacol. 2024 Oct 28;333:118505. doi: 10.1016/j.jep.2024.118505. Epub 2024 Jun 28. PMID: 38945466. (assisted in study design)
7. Li Z, Lin Y, Zou Y, Liang Y, Zeng L, Wang Y, et al. Zuogui pills ameliorate chemotherapy-induced ovarian aging by improving stemness, regulating cell cycle and reducing apoptosis of oogonial stem cells via the Notch1/Nrf2 pathway. J Ethnopharmacol. 2025 Jan 13;339:119105. doi: 10.1016/j.jep.2024.119105. Epub 2024 Nov 22. PMID: 39580130. (assisted in study design)

Focusing on reproductive and aging diseases.

Mainly studying the mechanisms, early diagnosis and potential therapies of ovarian aging and pregnancy-related diseases in clinical and basic science research, which helps improving female reproductive health.

She received her clinical training of Gynecology of Chinese Medicine in The First Affiliated Hospital, Guangzhou University of Chinese Medicine from 2017 to 2023, and specialized in diagnosis and prevention of ovarian aging and early pregnancy loss.

1. 2020    Outstanding M.D. Student and Graduation Thesis Award, GZUCM, awarded for distinguished performance in studying and thesis writing.

2. 2021    Excellent Paper Award, Department of Gynecology, Chinese Information Association of Traditional Chinese Medicine, awarded for distinguished performance in paper competition

3. 2021    Excellent Paper Award, 10^th Annal Meeting of Professional Committee of Obstetrics and Gynecology, Chinese Association of Integrative Medicine, awarded for distinguished performance in paper competition

4. 2022    First Prize of 13^th National Doctoral Dissertation Competition in TCM, China Journal of Traditional Chinese Medicine and Pharmacy, awarded for distinguished performance in paper competition.

5. 2022    National Scholarship of Graduate Student, Ministry of Education of the People's Republic of China, awarded for distinguished performance in study

5. 2023    Outstanding Ph.D. Student and Graduation Thesis Award, GZUCM, awarded for distinguished performance in studying and thesis writing

Active Grants

01/01/2021 – 12/31/2025        Co-Inv, 20% (PI: Songping Luo)

                                                “Study on the mechanism of the therapy of tonifying kidney for preventing miscarriage regulating trophoblast RNA m⁶A methylation to mediate the immunoregulation function of NK cells in maternal-fetal interface”

                                                The National Natural Science Foundation of China (NSFC) 82174424

                                                Annual Direct Costs: ¥137,500

                                                Total Direct Costs:      ¥550,000

                                                Project design, animal modeling, cell culture and conducting molecular experiments

01/01/2021 – 12/31/2025        Co-Inv, 5% (PI: Ling Zhu)

                                                “Study on the mechanism of regulating Notch1/Nrf2 signaling pathway by tonifying kidney and nourishing essence to improve histone acetylation of oogonial stem cells in premature ovarian insufficiency”

                                                NSFC 82174418

                                                Annual Direct Costs: ¥137,500

                                                Total Direct Costs:      ¥550,000

                                                Project design and guide

Completed Grants

01/01/2017-12/31/2020           Co-Inv 40% (PI: Ling Zhu)

                                                “Study of kidney-tonifying and essence-nourishing therapy on the oogonial stem cells in chemotherapy-induced premature ovarian failure rats based on Notch signaling pathway”

                                                  NSFC 81674016

                                                  Annual Direct Costs: ¥137,500

                                                  Total Direct Costs:      ¥550,000

                                                   Animal modeling, primary cell isolation and culture, conducting molecular experiments

2023-2025                               PI, 90%

“Mechanism study of RNA m⁶A modification in oocyte regeneration dysfunction of ovarian aging”

                                                The Postdoctoral Fellowship Program (Grade C) of China Postdoctoral  Science Foundation           

                                                 GZC20232689

                                               Annual Direct Costs: ¥120,000

                                               Total Direct Costs:      ¥240,000

1. Mouse handling: mouse breeding, diseases modeling, pharmacological research.

2. Molecular biology: PCR, western blot, HE staining, IHC, IF, FISH, MeRIP.

3. Cell culture: human/mouse/rat/guinea pig stem cells culture, primary cell isolation and cell line establishment, CRISPR and SiRNA.

4. Data analysis: SPSS, Stata, Adobe Illustrator, ImageJ, SnapGene, FlowJow.